^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    REST signature

    over1year
    EVALUATION OF NEW MACHINE LEARNING SYSTEMS FOR PROGNOSTICATION BASED ON GENE EXPRESSION SIGNATURES IN MANTLE CELL AND PERIPHERAL T CELL LYMPHOMAS (EHA 2023)
    MCL is currently treated with rituximab combined with chemotherapy, which frequently involves high doses of cytarabine, followed by an autologous stem cell transplantation (auto-SCT) in younger and fit patients. In conclusion, we prove that these prognostic signatures are also applicable to MCL and PTCL patients, thus broadening its applicability and simplifying the molecular tools needed to risk stratify patients with aggressive lymphomas. Its standardization and evaluation in the context of innovative therapeutic schemes is envisaged. Risk factor, Mantle cell lymphoma, Gene expression profile, Peripheral T-cell lymphoma
    Machine learning
    |
    REST signature
    |
    Rituxan (rituximab) • cytarabine
    2years
    MITF deficiency and oncogenic GNAQ each promote proliferation programs in zebrafish melanocyte lineage cells. (PubMed, Pigment Cell Melanoma Res)
    Finally, we show that this oncogene-induced proliferative phenotype can be used to screen chemical inhibitors for their efficacy against the UM pathway. Overall, this study establishes that a neural crest signature correlates with poor UM survival, and describes an in vivo assay for pre-clinical trials of potential UM therapeutics.
    Journal
    |
    BRAF (B-raf proto-oncogene) • GNAQ (G Protein Subunit Alpha Q) • MITF (Melanocyte Inducing Transcription Factor)
    |
    REST signature